[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.191.72. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 28, 2004

Ranolazine as Add-on Therapy for Patients With Severe Chronic Angina

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2004;291(16):1959. doi:10.1001/jama.291.16.1959-b

To the Editor: Dr Chaitman and colleagues1 did not present detailed safety data. In particular, we would be interested in knowing the effect ranolazine has on kidneys, liver, blood cells, or metabolism, as well as on quality of life and hospital admission rates. Furthermore, the authors reported that 30% to 41% of subjects stopped taking ranolazine, but they did not present their subsequent clinical events. The fate of these individuals is critical in assessing the safety of this drug.

First Page Preview View Large
First page PDF preview
First page PDF preview
×